Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Francis Crick Institute
Headquarters: London, United Kingdom
Website: http://www.crick.ac.uk
Year Founded: 2015
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Nov 15, 2024
Finance
Syncona building Slingshot incubator; Trace launches with $101M
BioCentury’s Financial Report also features venture rounds for Alentis and Metsera; follow-ons for Zai Lab and 89bio
BioCentury | Sep 16, 2024
Management Tracks
AZ veteran Pangalos joining Stampacchia’s Omega Funds
R&D leader will arrive at venture firm next month
BioCentury | Aug 1, 2024
Distillery Therapeutics
Inhibiting transcription factor ETS2 for autoimmune diseases
BioCentury | Jul 12, 2024
Management Tracks
J.P. Morgan adds Joseph Siletto as managing partner
Plus: Fresenius and NS Pharma name new presidents, and updates from The Francis Crick Institute, CIRM, Nuvalent and more
BioCentury | Apr 19, 2024
Management Tracks
Doug Williams leaving Sana
Plus: Baptista joins SmartCella and updates from LifeArc and Gain
BioCentury | Feb 3, 2024
Discovery & Translation
Science spotlight: RNA-based enzymes for DNA editing; plus XIST-driven autoimmunity and more
BioCentury’s roundup of translational innovations
BioCentury | Jan 30, 2024
Product Development
Singapore’s next challenge: turning momentum into sustainable growth
The island nation has caught the interest of international investors and pharmas. Will this be the moment its biotech accelerates?
BioCentury | Dec 13, 2023
Emerging Company Profile
Myricx: ADCs with a lipidation inhibitor payload
U.K.-based Myricx is turning a small molecule for parasitic diseases into an ADC payload for cancers
BioCentury | Sep 30, 2023
Discovery & Translation
DIOSynVax-Ethris sarbecovirus vaccine; plus CYR61 in NASH and more
BioCentury’s roundup of translational innovations
BioCentury | Nov 1, 2022
Product Development
Neoantigens Part II: cell therapies
An overview of the growing field, company players and emerging data
Items per page:
1 - 10 of 71